Biotech - Spark Newswire

4 minute read

Reported Late Tuesday March 7, FDA Accepts Mesoblast’s Resubmission Of The Biologic License Application For Remestemcel-L In Children With Steroid-Refractory Acute Graft Versus Host Disease As A Complete Response And Sets Goal Date Of August 2, 2023

March 8, 1:30 AM

Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration's (FDA) Office of Therapeutic

MESO

1 minute read

Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason

By Vandana Singh

March 7, 8:34 PM

The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…

ABBV

1 minute read

U.S. Senate Republican Leader McConnell Says Biden Tax Plan On Medicare Will Not See Light Of Day In House

By Happy Mohamed

March 7, 3:28 PM

- Reuters

SPY

1 minute read

Republican Lawmakers In Florida Filed Bills On Tuesday To Outlaw Most Abortions After Six Weeks Of Pregnancy, A Ban That Would Severely Undercut Abortion Access In The U.S. South If Passed By The State’s Republican-controlled Legislature.

By Happy Mohamed

March 7, 2:58 PM

- Reuters

SPY

1 minute read

Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success

By Vandana Singh

March 7, 2:37 PM

Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …

GOSS

2 minute read

FDA’s Regulatory Delay is The Reason For Novavax, Lucira Health’s Failure: WSJ Report

By Vandana Singh

March 7, 2:29 PM

Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb

LHDX

2 minute read

‘Qualigen Peer-Reviewed Journal Article Out Titled “The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100p Gene Expression In Cells And In An In Vivo Model Of Pancreatic Cancer”‘

By Happy Mohamed

March 7, 12:30 PM

https://www.mdpi.com/1420-3049/28/6/2452 Abstract The naphthalene diimide compound QN-302, designed to bind to G-quadruplex DNA sequences within the promoter regions of cancer-related genes, has high anti-proliferative

QGEN

1 minute read

Caris Life Sciences Announced A Strategic Research Partnership With Incyte To Augment Precision Medicine Approaches For Incyte’s Oncology Pipeline; Deal Terms Not Disclosed

By Benzinga Newsdesk

March 7, 7:39 AM

Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs. For drug candidates developed under the

INCY

3 minute read

Dupixent Application For Treatment Of Chronic Spontaneous Urticaria In Adults And Adolescents Accepted For FDA Review

By Happy Mohamed

March 7, 2:19 AM

Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review More than 300,000 people in the

REGN

3 minute read

FDA
News

Reported Late Monday March 06, BioMarin Provides Update On FDA Review Of ROCTAVIAN Gene Therapy For Adults With Severe Hemophilia A; FDA Extends PDUFA Target Action Date To June 30, 2023

By Happy Mohamed

March 7, 2:06 AM

FDA Extends PDUFA Target Action Date to June 30, 2023 SAN RAFAEL, Calif., March 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global biotechnology company dedicated to transforming

BMRN